Subtype
Uterine Neoplasm
CI-CAN-00004208Explore in graph →
Non-malignant926 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004208Explore in graph →
Clinical trials
3,824 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06042543 | Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs(EASTER) | recruiting | N/A | 3,200 | International Agency for Research on CancerOTHER | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06680739 | Single cEll pRofiling PErsistaNce To ImmuNothErapy(SERPENTINE) | recruiting | Phase 2 | 60 | Vall d'Hebron Institute of OncologyOTHER |
| 1 |
| Jun 1, 2026 |
| clinicaltrials |
| NCT07286188 | Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | recruiting | Phase 4 | 40 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07617818 | QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer | not yet recruiting | Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 692 | National Cancer Institute (NCI)NIH | 3 | May 29, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT05743517 | Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) | recruiting | N/A | 192 | Northwestern UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06153667 | Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)(BETTER-UAE) | recruiting | — | 100 | Merit Medical Systems, Inc.INDUSTRY | 3 | May 29, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07214506 | Human Papillomavirus (HPV) Self-Sampling Options to Promote Equity(HOPE) | not yet recruiting | N/A | 100 | University of ArizonaOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07613567 | A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer | not yet recruiting | Phase 3 | 486 | Fujian Cancer HospitalOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT07472153 | PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer | recruiting | Phase 2 / Phase 3 | 120 | N.N. Alexandrov National Cancer CentreOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT06430320 | Ascertaining Longterm Outcomes of Fibroid Treatments(ALOFT) | active not recruiting | — | 700 | Henry Ford Health SystemOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07605507 | Hypofractionated Whole Pelvic Chemoradiotherapy With iRex Optimization in Cervical Cancer(HYPOCx-iRex) | active not recruiting | N/A | 40 | Siriraj HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07606677 | Peripheral Blood CyTOF Immune Model for Cervical Lesion Detection in HPV16/18+ Women | not yet recruiting | — | 1,465 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT03008408 | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05359016 | Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique | active not recruiting | N/A | 9,014 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT07368205 | Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging(PRSTEC_multipr) | recruiting | — | 350 | University Hospital Hradec KraloveOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07594327 | Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer | enrolling by invitation | — | 21 | Tampere University HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07605247 | Tirzepatide in the Treatment of Endometrial Cancer(TREAT-EC) | not yet recruiting | Phase 2 | 30 | Rutgers, The State University of New JerseyOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT04219904 | PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04634617 | Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors | active not recruiting | — | 310 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07583329 | Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy(V-COSMOS) | not yet recruiting | — | 160 | Cukurova UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07597083 | Biofeedback-Assisted Pelvic Floor Rehabilitation for Radiation-Induced Sexual Dysfunction in Cervical Cancer Survivors | recruiting | N/A | 60 | Beni-Suef UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05761951 | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07595224 | Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer(PostOP HYPOCxE) | recruiting | N/A | 120 | Siriraj HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07593066 | PRIORITY Study in Cervical Cancer(PRIORITY) | not yet recruiting | — | 700 | Pontificia Universidad Catolica de ChileOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features(RAINBO) | recruiting | Phase 2 / Phase 3 | 1,615 | Leiden University Medical CenterOTHER | 4 | May 15, 2026 | clinicaltrials |
| NCT07205497 | QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer(QNACTH) | active not recruiting | Phase 2 | 54 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07572396 | Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities | recruiting | Phase 2 | 45 | Amplexd Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07581873 | Education and Health in Women With Cervical Cancer | active not recruiting | N/A | 28 | Federal University of MaranhaoOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors(N01-A-PICIT-GT) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05691504 | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT07400536 | A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT | recruiting | Phase 3 | 378 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04743674 | Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment | recruiting | — | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 2 | May 12, 2026 | clinicaltrials |
| NCT05029258 | Biomarkers for Clinical Hypoxia Evaluation in Cervical Cancer(Bio-CHECC) | active not recruiting | — | 30 | University of ManchesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581288 | Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression(MIRA) | not yet recruiting | — | 50 | University of British ColumbiaOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05979610 | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies(Reiki-Brachy) | recruiting | Phase 2 | 70 | University of UtahOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03932409 | Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer(FIERCE) | active not recruiting | Phase 1 | 45 | University of OklahomaOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05544084 | Adaptation and Implementation of a Patient Navigation Program for Cervical Cancer Screening Across Contexts in Senegal | recruiting | N/A | 901 | University of Illinois at ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07576842 | Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV | not yet recruiting | N/A | 750 | University of California, San DiegoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04713618 | Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy(GEORGIA) | active not recruiting | — | 72 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06790004 | Endometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy)(LPSvsLPT) | active not recruiting | — | 700 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 7, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 1, 2026source: clinicaltrials